Linezolid versus vancomicina para las infecciones de piel y partes blandas
Información
- DOI:
- https://doi.org/10.1002/14651858.CD008056.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 enero 2016see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Heridas
- Copyright:
-
- Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Yue Jirong: conceived the review question; co‐ordinated the protocol development; completed the first draft and edited the review.
Dong Birong: developed the review and advised on the review, co‐ordinated the review development and performed part of writing and editing of the review, approved the final version of the review prior to submission and is guarantor.
Yang Ming: developed and edited the review and made an intellectual contribution to it.
Chen Xiaomei: conceived the review question, edited the review and made an intellectual contribution to it.
Wu Taixiang: developed the review, advised and performed part of writing and editing of the review, and made an methodological contribution.
Liu Guanjian: advised and performed part of writing and editing of the review, and made a statistical contribution.
Contributions of editorial base
Nicky Cullum: edited the review; advised on methodology, interpretation and review content.
Julie Bruce, Editor: approved the final review prior to submission.
Sally Bell‐Syer: co‐ordinated the editorial process. Advised on methodology, interpretation and content. Edited and copy edited the review.
Ruth Foxlee: designed the search strategy and edited the search methods section.
Sources of support
Internal sources
-
Chinese Cochrane Center, China.
External sources
-
This project was supported by the National Institute for Health Research via Cochrane Infrastructure funding to Cochrane Wounds. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health, UK.
Declarations of interest
Yue Jirong: none known.
Dong Birong: none known.
Yang Ming: none known.
Chen Xiaomei: none known.
Wu Taixiang: none known.
Liu Guanjian: none known.
Acknowledgements
We would like to thank the following peer referees for their helpful comments on the review: Julie Bruce, Susan O’Meara, Ruth Foxlee, Jane Burch, Elmer Villanueva, Beryl de Souza, Brian Gilchrist, Patricia Davies, Shirley Manknell. Sally Bell‐Syer is especially acknowledged for language assistance, and Nicola Thomis for her contributions to the glossary. We also would like to acknowledge the copy editor, Elizabeth Royle, for edits to our draft.
Version history
| Published | Title | Stage | Authors | Version |
| 2016 Jan 07 | Linezolid versus vancomycin for skin and soft tissue infections | Review | Jirong Yue, Bi Rong Dong, Ming Yang, Xiaomei Chen, Taixiang Wu, Guan J Liu | |
| 2013 Jul 12 | Linezolid versus vancomycin for skin and soft tissue infections | Review | Jirong Yue, Bi Rong Dong, Ming Yang, Xiaomei Chen, Taixiang Wu, Guan J Liu | |
| 2009 Oct 07 | Linezolid versus vancomycin for skin and soft tissue infections | Protocol | Jirong Yue, Bi Rong Dong, Ming Yang, Xiaomei Chen, Taixiang Wu, Guan J Liu | |
Differences between protocol and review
-
Under "Types of outcome measures/Primary outcomes" in the sentence "Proportion of patients or infections healed: healing is defined as either the resolution of all clinical signs and symptoms of infection, as assessed by laboratory test or as defined by trialists", we changed to, "clinical cure (resolution of symptoms and signs) and microbiological cure (eradication of bacteria on wound culture)." We think the meaning of the two statements is the same, however, "clinical/microbiological cure" is more concise and helpful than the original wording when used throughout the text of the review.
-
In the section "Subgroup analysis and investigation of heterogeneity", we added:"3. MRSA subset", because MRSA is important for SSTIs. The morbidity and treatment costs associated with MRSA‐infected SSTIs are higher than for other pathogen infections, so we added this subgroup analysis.
-
We added some information in the "Background" section in line with comments from peer referees.
-
We added some information in the "Methods/Dealing with missing data" section, in line with comments from peer referees.
